Cargando…
Head & neck melanoma: A 22‐year experience of recurrence following sentinel lymph node biopsy
OBJECTIVE: To examine the clinicopathologic factors that contribute to regional and distant recurrence in intermediate to high risk head and neck melanoma patients after sentinel lymph node biopsy (SLNB). METHODS: This study is a retrospective review from an academic tertiary care center. Patients t...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356881/ https://www.ncbi.nlm.nih.gov/pubmed/34401498 http://dx.doi.org/10.1002/lio2.605 |
_version_ | 1783737028912873472 |
---|---|
author | Echanique, Kristen A. Ghazizadeh, Shabnam Moon, Andy Kwan, Kera Pellionisz, Peter A. Rünger, Dennis Elashoff, David St. John, Maie |
author_facet | Echanique, Kristen A. Ghazizadeh, Shabnam Moon, Andy Kwan, Kera Pellionisz, Peter A. Rünger, Dennis Elashoff, David St. John, Maie |
author_sort | Echanique, Kristen A. |
collection | PubMed |
description | OBJECTIVE: To examine the clinicopathologic factors that contribute to regional and distant recurrence in intermediate to high risk head and neck melanoma patients after sentinel lymph node biopsy (SLNB). METHODS: This study is a retrospective review from an academic tertiary care center. Patients treated with SLNB for head and neck melanoma from 1997 to 2019 were reviewed and characterized by sentinel lymph node (SLN) status. Clinical variables were examined for the impact on regional and distant recurrence in SLNB‐negative patients using univariable and multivariable Cox regression analysis. RESULTS: One hundred and fifty four patients were included. Of note, 127 (82.5 %) were men, and the average age was 61.3 years. Median follow‐up was 68.6 weeks. Pathologic review of SLNs found 3.9% positive for metastatic melanoma; 96.1% were negative. Regional recurrence was significantly associated with tumor stage and age on multivariate analysis. A total of 4.5% of patients recurred in a previously labeled negative basin. Scalp subsite accounted for 30.5% of primary tumors and was more likely to yield a positive SLN on univariate analysis (P = .023). Tumor stage and age were significantly associated with distant metastasis on multivariable analysis (P = .026, P < .001 respectively). CONCLUSION: We report a number of prognostic trends in head and neck melanoma. SLN positivity was found more often in patients with a primary tumor of the scalp. Regional recurrence was significantly associated with age and tumor stage, whereas distant recurrence was significantly associated with tumor staging and scalp subsite. Scalp subsite was associated with an increased risk for nodal metastasis and distant recurrence. LEVEL OF EVIDENCE: 3. |
format | Online Article Text |
id | pubmed-8356881 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83568812021-08-15 Head & neck melanoma: A 22‐year experience of recurrence following sentinel lymph node biopsy Echanique, Kristen A. Ghazizadeh, Shabnam Moon, Andy Kwan, Kera Pellionisz, Peter A. Rünger, Dennis Elashoff, David St. John, Maie Laryngoscope Investig Otolaryngol HEAD AND NECK, AND TUMOR BIOLOGY OBJECTIVE: To examine the clinicopathologic factors that contribute to regional and distant recurrence in intermediate to high risk head and neck melanoma patients after sentinel lymph node biopsy (SLNB). METHODS: This study is a retrospective review from an academic tertiary care center. Patients treated with SLNB for head and neck melanoma from 1997 to 2019 were reviewed and characterized by sentinel lymph node (SLN) status. Clinical variables were examined for the impact on regional and distant recurrence in SLNB‐negative patients using univariable and multivariable Cox regression analysis. RESULTS: One hundred and fifty four patients were included. Of note, 127 (82.5 %) were men, and the average age was 61.3 years. Median follow‐up was 68.6 weeks. Pathologic review of SLNs found 3.9% positive for metastatic melanoma; 96.1% were negative. Regional recurrence was significantly associated with tumor stage and age on multivariate analysis. A total of 4.5% of patients recurred in a previously labeled negative basin. Scalp subsite accounted for 30.5% of primary tumors and was more likely to yield a positive SLN on univariate analysis (P = .023). Tumor stage and age were significantly associated with distant metastasis on multivariable analysis (P = .026, P < .001 respectively). CONCLUSION: We report a number of prognostic trends in head and neck melanoma. SLN positivity was found more often in patients with a primary tumor of the scalp. Regional recurrence was significantly associated with age and tumor stage, whereas distant recurrence was significantly associated with tumor staging and scalp subsite. Scalp subsite was associated with an increased risk for nodal metastasis and distant recurrence. LEVEL OF EVIDENCE: 3. John Wiley & Sons, Inc. 2021-06-21 /pmc/articles/PMC8356881/ /pubmed/34401498 http://dx.doi.org/10.1002/lio2.605 Text en © 2021 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC. on behalf of The Triological Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | HEAD AND NECK, AND TUMOR BIOLOGY Echanique, Kristen A. Ghazizadeh, Shabnam Moon, Andy Kwan, Kera Pellionisz, Peter A. Rünger, Dennis Elashoff, David St. John, Maie Head & neck melanoma: A 22‐year experience of recurrence following sentinel lymph node biopsy |
title | Head & neck melanoma: A 22‐year experience of recurrence following sentinel lymph node biopsy |
title_full | Head & neck melanoma: A 22‐year experience of recurrence following sentinel lymph node biopsy |
title_fullStr | Head & neck melanoma: A 22‐year experience of recurrence following sentinel lymph node biopsy |
title_full_unstemmed | Head & neck melanoma: A 22‐year experience of recurrence following sentinel lymph node biopsy |
title_short | Head & neck melanoma: A 22‐year experience of recurrence following sentinel lymph node biopsy |
title_sort | head & neck melanoma: a 22‐year experience of recurrence following sentinel lymph node biopsy |
topic | HEAD AND NECK, AND TUMOR BIOLOGY |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356881/ https://www.ncbi.nlm.nih.gov/pubmed/34401498 http://dx.doi.org/10.1002/lio2.605 |
work_keys_str_mv | AT echaniquekristena headneckmelanomaa22yearexperienceofrecurrencefollowingsentinellymphnodebiopsy AT ghazizadehshabnam headneckmelanomaa22yearexperienceofrecurrencefollowingsentinellymphnodebiopsy AT moonandy headneckmelanomaa22yearexperienceofrecurrencefollowingsentinellymphnodebiopsy AT kwankera headneckmelanomaa22yearexperienceofrecurrencefollowingsentinellymphnodebiopsy AT pellioniszpetera headneckmelanomaa22yearexperienceofrecurrencefollowingsentinellymphnodebiopsy AT rungerdennis headneckmelanomaa22yearexperienceofrecurrencefollowingsentinellymphnodebiopsy AT elashoffdavid headneckmelanomaa22yearexperienceofrecurrencefollowingsentinellymphnodebiopsy AT stjohnmaie headneckmelanomaa22yearexperienceofrecurrencefollowingsentinellymphnodebiopsy |